Celadon Pharmaceuticals Plc

AIM:CEL Stock Report

Mkt Cap: UK£33.0m

We’ve recently updated our valuation analysis.

Celadon Pharmaceuticals Valuation

Is CEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CEL?

Other financial metrics that can be useful for relative valuation.

CEL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2490.6x
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does CEL's PB Ratio compare to its peers?

The above table shows the PB ratio for CEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.3x
STX Shield Therapeutics
AGY Allergy Therapeutics
POLB Poolbeg Pharma
EAH ECO Animal Health Group
CEL Celadon Pharmaceuticals

Price-To-Book vs Peers: CEL is expensive based on its Price-To-Book Ratio (3x) compared to the peer average (1.3x).

Price to Earnings Ratio vs Industry

How does CEL's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.9%

Price-To-Book vs Industry: CEL is good value based on its Price-To-Book Ratio (3x) compared to the UK Pharmaceuticals industry average (4.3x)

Price to Book Ratio vs Fair Ratio

What is CEL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CEL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CEL's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CEL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CEL's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies